Biomarkers and environmental risk assessment: Guiding principles from the human health field

Marine Pollution Bulletin

Volumn 56, Issue 4, 2008, Pages 613-619

  Owen, Richard ^a,b   Galloway, Tamara S ^d   Hagger, Josephine A ^a   Jones, Malcolm B ^a   Depledge, Michael H ^c  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b ENVIRONMENT AGENCY   (United Kingdom)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Biomarkers; Environmental risk assessment; Human health; Qualification; Validation

Indexed keywords

BLOOD PRESSURE; HEALTH RISKS; RISK ASSESSMENT;

ENVIRONMENTAL RISK ASSESSMENT (ERA); QUALIFICATION; VALIDATION;

BIOMARKERS;

BIOLOGICAL MARKER; CHOLESTEROL; DIBUTYLTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TRIBUTYLTIN; VITELLOGENIN;

BIOMARKER; ENVIRONMENTAL ASSESSMENT; HEALTH RISK; MODEL VALIDATION; PUBLIC HEALTH; RISK ASSESSMENT;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONCEPTUAL FRAMEWORK; CORONARY ARTERY ATHEROSCLEROSIS; ECOTOXICOLOGY; ENVIRONMENTAL EXPOSURE; HEALTH CARE MANAGEMENT; HEALTH HAZARD; HUMAN; NONHUMAN; POLLUTANT; QUALITY CONTROL; RISK ASSESSMENT;

ANIMALS; BIOLOGICAL MARKERS; ENVIRONMENTAL MONITORING; HEALTH STATUS INDICATORS; HUMANS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 41149160635     PISSN: 0025326X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.marpolbul.2008.01.022     Document Type: Article

References (35)

1. Biomarkers Definitions Working Group, 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Therap. 69, 89-95.
2. Birchenough A.C., Evans S.M., Moss C., and Welch R. Re-colonisation and recovery of populations of dogwhelks Nucella lapillus (L.) on shores formerly subject to severe TBT contamination. Marine Pollut. Bull. 44 (2002) 652-659
3. Bonassi S., and Au W.W. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat. Res. 511 (2002) 73-86
4. Bonassi S., Neri M., and Puntoni R. Validation of biomarkers as early predictors of disease. Mutat. Res. 480-481 (2001) 349-358
5. Bray S., and Herbert R.J.H. A reassessment of populations of the Dogwhelk Nucella lapillus on the Isle of Wight following legislation restricting the use of TBT antifouling paints. Proceedings of the Isle of Wight National Historical and Archaeological Society 14 (1998) 23-40
6. Bryan G.W., Gibbs P.E., Hummerstone L.G., and Burt G.R. The decline of the gastropod Nucella lapillus around South-west England: evidence for the effect of tributyltin from antifouling paints. J. Marine Biol. Assoc.UK 66 (1986) 611-640
7. Bryan G.W., Gibbs P.E., Burt G.R., and Hummerstone L.G. The effects of tributyltin (TBT) accumulation on adult dogwhelks, Nucella lapillus: Long-term field and laboratory experiments. J. Marine Biol. Assoc. UK 67 (1987) 525-544
8. Crothers J.H. Further observations on a population of dogwhelks, Nucella lapillus (Gastropoda) recolonizing a site following amelioration of tributyltin (TBT) pollution. J. Marine Biol. Assoc. UK 83 (2003) 1023-1027
9. Depledge M.H. The rational basis for detection of the early effects of marine pollutants using physiological indicators. Ambio (Royal Swedish Academy of Sciences) 18 (1989) 301-302
10. Depledge M.H. The rational basis for the use of biomarkers as ecotoxicological tools. In: Fossi M.C., and Leonzio C. (Eds). Nondestructive Biomarkers in Vertebrates (1994), Lewis Publication, Boca Raton 61-285
11. Depledge M.H., Amaral - Mendes J.J., Daniel B., Halbrook R.S., Kloepper-Sams P., Moore M.N., and Peakall D.B. The conceptual basis of the biomarker approach. NATO ASI Series. H68 (1993) 15-29
12. Devendra D., Galloway T.S., Horton S.J., and Wilkin T.J. Exploring the Idiotypes of insulin antibodies as markers of metabolic remission in type 1 diabetes. Diabetic Medicine 21 (2004) 1316-1324
13. Devendra D., Galloway T.S., Horton S.J., and Wilkin T.J. Distinct idiotypes of insulin autoantibody in autoimmune polyendocrine syndrome type 2 and childhood onset type 1 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 5266-5270
14. Devlin M., Best M., and Haynes D. Implementation of the water framework directive in European marine waters. Marine Pollut. Bull. 55 (2007) 1-282
15. Evans S.M., Leksono T., and Mc Kinnell P.D. Tributyltin pollution: a diminishing problem following legislation limiting the use of TBT-based anti-fouling paints. Marine Pollut. Bull. 30 (1995) 14-21
16. Fleming T.R., and DeMets D.L. Surrogate endpoints in clinical trials: are we being mislead?. Ann. Internal Med. 125 (1996) 605-613
17. Frank B., Galloway T.S., and Wilkin T.J. Developments in the prediction of type 1 diabetes mellitus, with special reference to insulin autoantibodies. Diabetes Metab. Res. Rev. 21 (2005) 395-415
18. Galloway T.S., Fewster D., Crocker D., Noor M., and Wilkin T.J. Time clustering of high titre insulin autoantibodies in the cord blood of infants born to non-diabetic mothers. Autoimmunity 32 (2000) 17-26
19. Garaj-Vrhovac V., and Zeljezic D. Assessment of genome damage in a population of Croatian workers employed in pesticide production by chromosomal aberration analysis, micronucleus assay and comet assay. J. Appl. Toxicol. 22 (2002) 249-255
20. Gibbs P.E., and Bryan G.W. Reproductive failures in populations of the dogwhelk, Nucella lapillus, caused by imposex induced by tributyltin from antifouling paints. J. Marine Biol. Assoc. UK 66 (1986) 767-777
21. Gibbs P.E., Pascoe P.L., and Burt G.R. Sex change in the female dogwhelk, Nucella lapillus, induced by tributyltin from antifouling paints. J. Marine Biol. Assoc. UK 68 (1988) 715-731
22. Goodsaid F., and Frueh F. Biomarker qualification pilot process at the US food and drug administration. AAPS J. 9 (2007) E105-E108
23. Hagger J.A., Jones M.B., Leonard D.R.P., Owen R., and Galloway T.S. Biomarkers and integrated environmental risk assessment: are there more questions than answers?. Integr. Environ. Assess. Manage. 2 (2006) 312-329
24. Hilsenbeck S.G., and Clark G.M. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J. Cellular Biochem. 17G (1993) 205-211
25. Hulka B.S. Epidemiological studies using biological markers: issues for epidemiologists. Cancer Epidemiol. Biomark. Prev. 1 (1991) 13-19
26. Kidd K.A., Blanchfield P.J., Mills K.H., Palace V.P., Evans R.E., Lazorchak J.M., and Flick R.W. Collapse of a fish population after exposure to a synthetic estrogen. Proc. Nat. Acad. Sci. USA 104 (2007) 8897-8901
27. Lippman S.M., Lee J.S., Lotan R., Hittelman W., Wargovich M.J., and Hong W.K. Biomarkers as intermediate end points in chemoprevention trials. J. Nat. Cancer Inst. 82 (1990) 555-560
28. Perera F.P. Molecular epidemiology: on the pathway to prevention?. J. Nat. Cancer Inst. 92 (2000) 602-612
29. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8 (1989) 431-440
30. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Brit. J. Clin. Pharmacol. 44 (1997) 215-219
31. Scandinavian Simvastin Survival Study Group, 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin Survival Study. Lancet 344, 1383-1389.
32. Schatzkin A., Freedman I., and Schiffman M. An epidemiological perspective on biomarkers. J. Internal Med. 233 (1993) 75-79
33. Suter II G.W. Endpoints for regional ecological risk assessments. Environ. Manage. 14 (1990) 9-23
34. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers 18 (2002) 41-46
35. Wagner J.A., Williams S.A., and Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Therap. 81 (2007) 104-107